Bluewillow Biologics Inc., of Ann Arbor, Mich., formerly Nanobio Corp., said it received an NIH Small Business Innovation Research grant to develop an intranasal Nanovax vaccine for the prevention of chlamydia. The one-year award will fund in vivo studies combining the firm's Nanovax technology with a proven chlamydia antigen.